NEW YORK (GenomeWeb News) — Ipsogen said today it has received ISO 13485 certification covering the manufacture and sale of in vitro diagnostic medical devices at its headquarters in Marseille, France.
The certification covers Ipsogen’s blood-based IVDs for molecular analysis, diagnosis, prognosis, and follow-ups in cancer patients.
Ipsogen CEO Vincent Fert said the certification shows “compliance with a significant part of the FDA Quality System Regulation."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.